AstraZeneca revenue surges $11.39 billion, but sees COVID vaccine sales decline

By Cecilia Butini

AstraZeneca PLC said Friday that it expects sales of its Covid-19 medicines, including its vaccine, to decline by a low-to-mid twenties percentage during the year, but reported higher revenue in the first quarter on the back of previous vaccine contracts.

The Anglo-Swedish pharma giant said that revenue rose to $11.39 billion in the first quarter from $7.32 billion the year prior, due to contribution from medicines of acquired company Alexion Pharmaceuticals and Covid-19 vaccine contracts that are awaiting delivery this year.

The company said that earnings before interest, taxes, depreciation and amortization were negatively affected by a $1.18 billion unwind of investory fair value uplift recognized on the acquisition of Alexion. The metric was $2.19 billion in the quarter, down from $2.69 billion the year prior.

Net profit in the first quarter was $386 million, down from $1.56 billion the year prior.

Core earnings per share rose to $1.89 in the quarter, a 16% increase from the previous year, AstraZeneca said.

Looking ahead, AstraZeneca said that it expects total revenue to increase by a high-teens percentage in 2022, while core EPS is expected to increase by a mid-to-high twenties percentage. Considering the expected decline in the sales of Covid-19 medicines, however, AstraZeneca said that gross margin from those medicines is expected to be lower than company average.

Write to Cecilia Butini at

This article was originally published by Read the original article here.

Previous articleElon Musk discussed layoffs and monetizing Twitter with bankers during deal negotiations: report
Next articleDow Jones Newswires: China’s Politburo vows to meet economic targets with more policy support


Please enter your comment!
Please enter your name here